2017 Legal Cannabis Market Developments

NEW YORK, January 11, 2017 /PRNewswire/ --

http://www.Financialbuzz.com - The future of the legal cannabis market depends on a variety of factors. Politically, some have expressed concerns regarding the incoming elected administration, others feel more optimistic after nine states have voted this election cycle. The results overwhelmingly came in favor of legalization of cannabis for medical and recreational use. Economically, the industry has shown tremendous growth year to year. According to a research published on January 3rd 2017 by ArcView Group, the legal cannabis sales in the U.S. last year reached $6.7 billion, a growth of 30 percent from 2015. Sales are projected to increase to $20.2 billion by the year 2021 representing a 25 percent compound annual growth rate. MassRoots, Inc. (OTC: MSRT), Cara Therapeutics Inc. (NASDAQ: CARA), Insys Therapeutics Inc. (NASDAQ: INSY), GW Pharmaceuticals (NASDAQ: GWPH), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE)

In an interview to Forbes, Arcview's editor-in-chief Tom Adams said that, "the only consumer industry categories I've seen reach $5 billion in annual spending and then post anything like 25% compound annual growth in the next five years are cable television (19%) in the 1990's and the broadband internet (29%) in the 2000's." ArcView Chief Executive Officer Troy Dayton added, "One of the biggest stories was the alternative forms of ingestion… Concentrates and edibles are becoming customer favorites versus traditional smoking."  

MassRoots, Inc. (OTCQB: MSRT) offers technology platforms for the cannabis industry. The Company's mobile applications enable consumers to provide community-driven reviews of cannabis strains and products, enabling consumers to make cannabis purchasing decisions. Yesterday the company announced that the company has launched an update to iOS mobile application, available through the Apple App Store.

In a press release MassRoots described the new features, "Geo-targeted native advertisements in MassRoots' local, buds and global feeds, enabling businesses to target advertisements to cannabis consumers in their local area. In depth strain and product pages with high quality photos and descriptions, enabling users to learn about their favorite strains and products and see what fellow enthusiasts have to say about them. Revamped reporting and content screening mechanisms, in addition to an enhanced geo-fence, to ensure MassRoots remains in compliance with state cannabis regulations and the Cole Memorandum."

MassRoots CEO Isaac Dietrich said in a statement, "Management believes that this update offers cannabis consumers the easiest way to find the best products at their local dispensary… The Company prides itself on our ability to leverage new technology in order to better serve the regulated cannabis industry. We look forward to continuing to introduce new features to our mobile applications to increase user engagement and drive revenue growth."

Clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, Cara Therapeutics Inc. (NASDAQ: CARA), has recently announced that it has completed patient enrollment for the multi-dose phase of its adaptive Phase 2/3 trial of I.V. CR845 in dialysis patients suffering from moderate-to-severe uremic pruritus. "We're very pleased to have completed enrollment as planned for Part A of the Phase 2/3 trial in pruritus associated with chronic kidney disease, as these eight-week data will determine the optimal dosing to carry forward into planned registration trials. In our previous Phase 2 trial, I.V. CR845 significantly reduced itch and improved the quality of life for dialysis patients with this condition over a two-week treatment period," said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. "We look forward to reporting top-line data from Part A of this trial in the first quarter of 2017 and, based on the results, initiating the planned registration phase later in the year."

Insys Therapeutics Inc. (NASDAQ: INSY) is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The company markets Subsys, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the US. Its lead product candidate is Syndros, an orally administered liquid formulation of dronabinol. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates.

GW Pharmaceuticals (NASDAQ: GWPH) is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. Epidiolex is GW's lead cannabinoid product candidate and is a proprietary oral solution of pure plant-derived cannabidiol, or CBD. GW's Epidiolex development is initially concentrating on severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. The company's current Phase 3 pivotal trials program for Epidiolex includes two Phase 3 trials in Dravet syndrome, two in LGS, one in TSC, and one in IS. The first two of these Phase 3 trials, one in Dravet syndrome and one in LGS, have showed significantly greater reductions in specific seizure types for patients taking Epidiolex compared to those taking placebo.

Clinical-stage pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs, Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) is currently in development of two proprietary products: a transdermal synthetic cannabidiol gel for refractory epilepsy, osteoarthritis and Fragile X syndrome and a novel synthetic THC pro-drug transdermal patch for two pain indications fibromyalgia and peripheral neuropathic pain.

Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and PR marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site for advertising such companies. Financialbuzz.com has been compensated tweleve thousand dollars for financial news dissemination and PR services by a third party non affiliate for massroots inc. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on this site along with other financial news PR media services. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com

For further information:

Media Contact: info@financialbuzz.com , +1-877-601-1879

SOURCE FinancialBuzz.com